JP2023501113A - Inhaler with stress monitoring - Google Patents

Abstract

The present disclosure is an aerosol-generating inhaler (100, 200) comprising a housing having an air flow path defined between an air inlet (102) and an air outlet (103) of the housing, The air outlet is a galvanometer disposed on the body of the housing and the inhaler that allows the generated aerosol to exit, measuring the galvanic skin response to measure the stress level of the inhaler user. and a controller (206) configured to control the emission of the aerosol based on the identified stress level.

Description

The present invention relates to an aerosol-generating inhaler having a sensor for monitoring a user's stress level during use.

Inhalers such as electronic cigarettes or vaping devices are becoming increasingly popular. They are used to deliver flavors or stimulants to the user in the form of an aerosol without burning. Users of such inhalers may wish to control the amount of flavor or stimulant released based on their preferences or other factors.

Vaping devices available on the market are often standardized and may not meet individual needs.

Accordingly, there is a need for a device that is compatible with its user and capable of controlling the delivery of aerosols in a safe and reliable manner.

According to one aspect of the invention, a housing has an air flow path defined between an air inlet and an air outlet of the housing, the air outlet permitting the generated aerosol to exit. a housing; and a galvanometer disposed on the body of the inhaler, the galvanometer being configured to measure galvanic skin response to determine the stress level of the user of the inhaler. a controller configured to control the emission of the aerosol based on the stress level obtained.

Advantageously, the inhaler of the present invention can identify the user's stress level during vaping and, based on that control, the amount of aerosol delivered to the user for inhalation. Since the galvanometer is integrated into the inhaler itself, the user does not have to make any extra effort or couple any additional device to the inhaler. Moreover, it is possible to maintain the user's stress at a baseline or optimal level while vaping, as the substances contained in the aerosol are adjusted according to the user's current stress level.

The galvanometer is preferably integrated into the activation switch of the inhaler such that when the user interacts with the activation switch to activate the inhaler, the user's skin contacts the galvanometer.

Advantageously, the galvanometer is activated when the user turns on the inhaler with the activation button, so the user does not need to perform any additional steps for stress level determination.

The galvanometer is preferably arranged on the side of the inhaler so that when the user holds the inhaler during use, the user's skin is in contact with the galvanometer.

Advantageously, stress level monitoring can be performed continuously while the user is using the inhaler.

The inhaler preferably also includes an accelerometer to detect the user's movements when using the inhaler.

Advantageously, it is possible to detect if the user is performing any physical activity that may affect the stress level reading.

The controller is preferably configured to ignore galvanic skin response measured by the galvanometer based on motion detected by the accelerometer.

Advantageously, the stress level, as determined by the accelerometer, is a stress reading taken at times that may be erroneous, such as when physical activity is being performed by the user while using the inhaler. By ignoring the value, it can be specified more precisely.

The controller is preferably configured to determine a baseline galvanic skin response for the user using measurements made by the galvanometer over different time periods.

Advantageously, by recording stress level data over a period of time, it is possible to identify a user's optimal or normal stress level while vaping.

The reference galvanic skin response preferably includes a range having an upper reference limit and a lower reference limit. The baseline galvanic skin response may also include a safety threshold, and the controller may be configured to take action if the safety threshold is exceeded.

Advantageously, having a reference range with upper and lower thresholds provides greater flexibility and allows for more realistic adjustments to the inhaler to the benefit of the user.

Preferably, the controller is configured to increase or decrease the amount of substance in the aerosol emission when the measured galvanic skin response is lower or higher than the reference galvanic skin response, respectively. The controller may also be configured to increase or decrease the amount of substance in the emitted aerosol based on time of day or data related to user vaping behavior including duration of vaping puffs or frequency of vaping puffs.

Advantageously, the user's stress level can be optimized by controlling the amount of aerosol based on the measured stress level.

The controller is configured to determine the number of puffs inhaled by the user per unit time.

Advantageously, it is also possible to determine the user's stress level based on the frequency or duration of puffs inhaled while vaping.

According to another aspect of the invention, there is provided a method of operating an aerosol-generating inhaler comprising actuating the inhaler to emit an aerosol from the inhaler and measuring galvanic skin response to determine the body of the inhaler. A method is provided that includes determining a user's stress level with a galvanometer disposed thereon and controlling aerosol emission based on the determined stress level.

1 shows an inhaler with a stress sensor according to an aspect of the invention; Figure 3 shows an inhaler with a stress sensor according to another aspect of the invention; 1B is a block diagram of various components in the inhaler of FIGS. 1A and 1B; FIG. FIG. 1B is a flow diagram for the operation of the inhaler of FIGS. 1A and 1B; FIG. 1B is a flow diagram for the operation of the inhaler of FIGS. 1A and 1B; 1 is a graph showing patterns of stress levels of a user during a typical week; Fig. 10 is a graph showing a comparison of a user's measured galvanic skin response to baseline limits at different time periods;

Various aspects of the invention are now described. It should be noted that, in the following description of the drawings, the same or similar parts are denoted by the same or similar reference numerals. It should be noted that the drawings are schematic representations and the proportions of the respective sizes are different from the actual ones. Therefore, specific sizes and the like should be determined in consideration of the following description. Needless to say, there are portions with different size relationships and ratios between the drawings.

FIG. 1A shows a non-combustion flavor inhaler 100, which is a device for inhaling flavors without burning them. The inhaler 100 has a rod-like shape with a body 101 extending from a non-mouthpiece end 102 to a mouthpiece end 103 . An air channel or pathway is defined within body 100 between opposing ends 102 , 103 . Inhaler 100 in this embodiment is an electronic cigarette or vaping device. Inhaler 100 functions by vaporizing or heating an aerosol source contained within inhaler 100 to release a flavor or stimulant for inhalation through mouthpiece end 103 by the user. The construction and operation of such inhalers are well known in the art and will be understood by those skilled in the art.

Inhaler 100 also includes an activation switch 104 that may be configured to power on and/or power off inhaler 100 . Activation switch 104 may be a push button or touch button disposed at any convenient location on the surface of body 101 of inhaler 101 .

Modern people want to monitor their activity level, physical condition, sleep quality, etc. for various reasons. There are several devices or gadgets available on the market that can do that. However, such devices may be wearable devices that may be considered too intrusive by some users, or other non-wearable devices that may not be convenient to use or carry. Either.

Monitoring stress levels is of particular interest because stress affects a variety of other bodily functions. For example, when a person experiences high levels of stress, his or her heart rate, blood pressure, and brain activity can increase, which can adversely affect health. However, some increased level of stress may be preferable in certain situations, such as during exams, difficult tasks, or emergencies. There are several activities that can increase stress levels such as strenuous exercise, substance intake, or emotional depression. Keeping track of stress levels and controlling external stimuli accordingly can help maintain good general health. It may also be desirable for users of electronic cigarettes or similar devices to control their aerosol intake based on their current stress level.

According to one aspect of the present invention, the stress sensor 204 detects when the user touches or presses the switch 104 to power up the inhaler 100 and the sensor 204 senses the user's stress level by skin contact as will be described in detail below. Integrated into the switch 104 to measure.

FIG. 1B shows an inhaler 200 similar to the inhaler 100 shown in FIG. 1A with one difference. That is, in the inhaler 200, the stress sensor 204 is arranged on the side surface 105 of the main body instead of the activation switch 104. As shown in FIG. The sensor 204 may be provided in the form of a strip or tag, and when a user holds the inhaler 200 during use, his or her skin contacts the sensor 204 which identifies the user's stress level. may be positioned to allow

It should be appreciated that the inhalers 100, 200 may be of any suitable shape and size and may have different functional mechanisms. Also, the activation switch 104 may be located on either the side or the bottom of the inhaler. The sensor 204 is preferably arranged to contact the user's skin during normal use without the user having to explicitly position and contact the sensor.

FIG. 2 shows various components of the inhaler 100,200. The inhaler 100, 200 includes an aerosol source 201 and a vaporizer 202 that vaporizes the aerosol source 201 to release an aerosol containing flavors and/or stimulants for inhalation by a user. In this example, the aerosol source 201 is a substance containing nicotine. Aerosol source 201 may be in solid or liquid form and is heated by a vaporizer (including a heat source) to release an aerosol without combustion. The vaporizer includes a heating coil to vaporize a liquid, or a heating chamber to heat a solid aerosol source (e.g., tobacco stick) without burning, or any other suitable configuration applicable to an aerosol generating device. can contain. Vaporizer 202 may be powered by power supply 203 . Power source 203 is, for example, a lithium ion battery. A power supply 203 provides the power necessary for operation of the inhaler 100,200. For example, the power supply 203 powers all other components or modules included in the inhaler 100,200.

The aerosol source 201 may include an additional flavor source (not shown) provided on the side of the mouthpiece end 103 beyond the holder holding the aerosol source 201 to allow the aerosol generated from the aerosol source 201 to flow with the user. produces flavors that are inhaled by Examples of flavor sources that can be used include cut tobacco, shaped bodies containing tobacco material shaped into granules, and shaped bodies containing tobacco material shaped into sheets. Flavor sources may include botanicals such as mint or herbs. Flavors such as menthol may be added to the flavor source.

Inhaler 100, 200 further includes a stress sensor. The stress sensor is preferably a galvanometer 204 that measures the skin potential of the user. Specifically, the galvanometer 204 identifies the user's stress level by measuring the galvanic skin response (GSR), or skin conductance, resulting from changes in sweat gland activity that reflects the user's emotional state. Since skin conductance is typically captured from the hand and foot regions, the electrodes present within galvanometer 204 come into contact with the user's hands when the user uses the inhaler.

The inhaler 100, 200 also includes a controller 206 configured to control various modules or components within the inhaler. Controller 206 also processes data captured by galvanometer 204 as described above.

Inhaler 100 , 200 may further include an accelerometer 205 . Accelerometer 205 is configured to measure user movement when using the inhaler. A user's galvanic skin response can be increased by strenuous physical movement, such as during exercise or brisk walking. In such cases, the galvanometer 204 may identify the user as having a high stress level, which is not necessarily in response to emotional stress. To minimize distortion in stress determination caused by vigorous movement, the user is preferably still to obtain accurate readings. Therefore, measurements made by galvanometer 204 during any violent motion can be ignored by controller 206 . However, such exercise data may be recorded for other purposes, such as for heart rate determination or for general user reference.

Inhaler 100 , 200 may also include puff detector 207 . In one embodiment, puff detector 207 is connected to a pressure sensor (not shown) that detects the air pressure caused by the user's inhalation action. The puff detector 207 detects the puff state based on the detection result of the sensor (for example, the negative pressure inside the inhaler 100, 200). Thus, the puff detector 207 can identify the number of puffs to inhale the aerosol. The puff detector 207 can also detect the time required for one puff to inhale the aerosol.

The inhaler 100, 200 may include memory 208, light emitting elements 209 and other modules 210 such as displays and sound emitters. A light emitting element 209 such as an LED may be disposed at the tip of the non-mouthpiece end 102 . Such an LED may exhibit a first emission mode in a puffed state with aerosol inhaled and a second emission mode different from the first emission mode in a non-puffed state with no aerosol inhaled. Here, the light emission mode is defined by a combination of parameters such as the light intensity of the light emitting elements, the number of light emitting elements in the lit state, the color of the light emitting elements, and the cycle of repeating lighting and non-lighting of the light emitting elements. Different emission modes means that at least any one of the above parameters is different.

FIG. 3A shows a flow diagram 300A of the operation of the inhaler 100,200. At step 301, the aerosol generator is activated. In this embodiment, aerosol source 201 may heat or vaporize and release an aerosol when a user presses activation switch 104 on inhaler 100 . A predetermined actuation of the switch 104, such as a predetermined number of consecutive depressions, powers on the inhaler 100,200. When power source 203 is turned on by operating switch 104 , power source 203 powers vaporizer 202 , galvanometer 204 , controller 206 and other components within inhaler 100 , 200 .

At step 302, the user's baseline GSR or stress range is identified. In this embodiment, controller 206 calculates a baseline GSR for the user based on readings obtained from galvanometer 204 over time, ie, through a continuous learning process. A baseline galvanic skin response may be used as an indicator of a user's optimal stress level. Since a user's stress level can vary throughout the day depending on several factors, it is preferable to define a reference GSR range by an upper GSR limit and a lower GSR limit. The reference range includes all GSR values within the upper and lower limits for a given time period. This allows for more flexible monitoring of stress levels. Moreover, each user has a different "normal" skin conductance, and it may not be possible to set a fixed value as a reference. The reference range for a user may be modified over time as more user data becomes available. It should be appreciated that the reference range may be stored in device memory 208 and simply fetched by controller 206 at step 302 .

A safe upper limit is also provided, which is generally higher than the GSR upper limit. GSR measurements above the upper safe limit are considered indicative of abnormal stress levels that are potentially harmful or potentially harmful. A safe upper limit or threshold may be pre-specified for all users. Alternatively, the upper safe limit may be calculated based on user-specific factors such as age, weight, and gender.

At step 303, the user's galvanic skin response is measured. In this example, the galvanometer 204 activates the electrodes to measure the user's galvanic skin response when the user presses the activation switch 104 in the inhaler 100 and/or holds the inhaler 200 from the side. Measure. As explained above, the user's stress level is determined based on the galvanic skin response. In this example, galvanometer 204 transmits the measured galvanic skin response reading to controller 206 to identify the user's stress level. The controller 206 may preferably average multiple readings received and determine the user's stress level based on algorithms and recorded user historical data.

At step 304, it is determined whether the measured GSR is within the reference range. In this embodiment, controller 206 determines whether the measured GSR obtained in step 303 falls within the reference GSR range identified or retrieved in step 302 . In comparison, the controller 206 determines whether the measured GSR is outside the upper or lower reference limits. Otherwise, controller 206 proceeds to step 305 , else proceeds to step 306 . In this example, if the measured GSR is not within the reference range, the measured GSR should either be above the upper reference limit or below the lower reference limit.

At step 305, the amount of substance in the aerosol is maintained. In this example, if the measured GSR is within the reference range, controller 206 concludes that the user's stress level is within the optimal range, and therefore continues delivery of aerosol from source 201 without change. may By doing so, the same amount of substance (such as nicotine) as before continues to be inhaled by the user.

At step 320, it is determined whether the measured GSR is above the upper safe limit. As noted, GSR levels above the upper safe limit are considered abnormal. In this example, upon determining that the measured GSR is above the upper safe limit, controller 206 performs safe action at step 321 . Safety actions may include reducing the amount of substance in the aerosol or suspending operation of the inhaler 100,200. Additionally or alternatively, the safety operation of controller 206 may include generating a visual warning using light emitting element 209 or sounding an audible alarm. These may be interpreted by the user as warning messages so that they can take countermeasures to reduce their stress level so that they are back below the upper safe limit.

At step 306, it is determined whether the measured GSR is above the upper reference limit. In this example, upon determining that the measured GSR is outside the reference range but still below the upper safe limit, the controller 206 further determines whether the measured GSR exceeds the upper reference limit, which is the threshold for increased GSR. identify. If the user's GSR is higher than the upper reference limit, but within a safe level (i.e., below the upper safe limit), it may indicate that the user is under higher than normal stress, so the controller 206, in step 308, proceed to On the other hand, if the measured GSR does not exceed the upper reference limit, the controller 206 provides only two options: either the out of reference range result from step 304 is above the upper reference limit or below the lower reference limit. Therefore, we conclude that the measured GSR value is below the lower reference limit. In this case, controller 206 proceeds to step 307 .

At step 307, the controller 206 is configured to control the amount of substance in the aerosol based on user preferences or other data. In this example, if the measured GSR is outside the reference range but does not exceed the upper reference limit, controller 206 concludes that the measured GSR value is below the lower reference limit, indicating a very low stress level. When nicotine is used as the substance, it is well known that certain amounts of nicotine are useful in reducing stress and calming the user. On the other hand, increased nicotine levels may also provide mental alertness and aid concentration. While a lower GSR value may indicate that the user is calm and at ease, it may equally indicate that the user feels lethargic and is having trouble coping with work. In one scenario, the controller 206 can control the amount of substance in the aerosol to maintain relaxed physiology and low stress levels. This may be achieved by maintaining the amount of substance in the aerosol or by decreasing the amount of substance, depending on user preference. In one example, the controller 206 can maintain or decrease the amount of substance based on the time of day, such as after 8:00 pm. For example, at night, users may prefer to maintain a relaxed physiology so that they can have uninterrupted sleep. The controller 206 can also maintain or decrease the amount of substance in the aerosol based on other data such as frequency of vaping. It has been found that the frequency of vaping, or the duration of vaping puffs, can indicate a user's state of relaxation, and less frequent vaping can indicate a user's desire to remain relaxed. . Accordingly, the controller can maintain or reduce the amount of substance in the aerosol in step 307 if the frequency of vaping or the duration of vaping puffs is below a predetermined threshold. In another scenario, at step 307 controller 206 may increase the amount of substance in the aerosol. This can be done to increase the GSR value so that it is again within the reference range. This may be particularly desirable during working hours when the user may wish to maintain normal stress levels. In this scenario, at step 307 the controller 206 can increase the amount of substance in the aerosol to provide a boost and make the user more active and alert. This may be done in many ways. In one example, the amount of aerosol emitted from source 201 may be increased, thereby increasing the amount of material inhaled by the user. In another embodiment, a multi-tank vaping device may be used that includes two or more liquid reservoirs each containing liquid having a different concentration of substance. By switching the supply to a reservoir containing a higher concentration of liquid, it is possible to increase substance uptake while maintaining the same aerosol volume. In yet another embodiment, substance delivery is controlled by controlling the heating action in heated non-combustion and steam-based devices (eg, by controlling the energy supplied to the heater) or by heating in steam-based devices. It can be increased by controlling the pressure liquid source. The controller 206 can increase the amount of substance in the aerosol based on user preferences or other data such as time of day or frequency of vaping. In particular, controller 206 may increase the amount of substance in the aerosol at step 307 when the time of day coincides with the user's normal work pattern. This may be preset as 9am-5pm Monday-Friday, but it may be adjusted based on user preferences or other data indicative of different work patterns. Controller 206 may also obtain data regarding the frequency of vaping or the duration of vaping puffs at step 307 and may increase the amount of substance in the aerosol if the frequency of vaping is above a predetermined threshold. When users desire to maintain normal wakefulness, they have been found to vape more frequently or with longer puffs, which achieves the desired wakefulness based on GSR measurements. such as may be detected by controller 206 .

At step 308, the amount of substance in the aerosol is increased. In this example, if the user's GSR exceeds the upper reference limit, it may indicate that the user is agitated or in a state of high stress. Certain amounts of nicotine can be useful in reducing stress and calming the user, and it has also been observed that smokers tend to smoke more under high stress. Thus, if the user's GSR is determined to be above the upper reference limit but still within the safe range (i.e., below the safe limit), the controller 206 increases the amount of substance in the aerosol to keep the user calm down.

FIG. 3B shows a flow diagram 300B of additional optional steps in the process of FIG. 3A. It should be appreciated that the steps at 300B are preferred but not required for the functioning of the invention.

Continuing from step 304, controller 206 determines whether the measured GSR is within the reference range as described above. If the measured GSR is determined to be within the reference range, controller 206 proceeds to step 309 , else proceeds to step 310 .

At step 309 it is determined whether longer or more frequent puffs have been detected. In this embodiment, puff detector 207 senses each time the user ingests a puff of aerosol through inhaler 100 . Puff detector 207 continuously monitors the frequency and duration of puffs made by the user and provides this puff data to controller 206 . Controller 206 preferably compares the puff frequency and duration to the user's puff history data, which may be stored in memory 208 . If the controller 206 determines that the puffs are more frequent and/or longer than normal, then the controller 206 proceeds to step 311 , else proceeds to step 312 .

At step 311, the amount of substance in the aerosol is increased. In this example, identifying more frequent and/or longer puffs may cause the controller 206 to conclude that the user desires a higher substance intake, and thus the aerosol delivered to the user. Increases the amount of substance inside. In this manner, user preferences are handled without requiring user intervention. Additionally, by continuously monitoring a user's vaping patterns, baseline values for puff frequency and length can be identified. Deviations from baseline values can also help identify emotional states. For example, longer and more frequent puffs may indicate a more stressful condition.

At step 312, the amount of substance in the aerosol is maintained. In this example, if the controller 206 determines that the frequency and duration of puffs, as interpreted from the puff history data, is normal, the controller 206 takes no further action and administers the same amount of substance as before. Continue to deliver the aerosol you have.

Returning to step 304, if the measured GSR is found to be outside the reference range, then in step 310 it is determined whether any vigorous user movement is detected. In this example, the accelerometer 205 detects any vigorous movement by the user while vaping, such as brisk walking. It is known that such movement may increase a user's GSR, but is not necessarily indicative of stress levels. Accelerometer 205 preferably provides such motion data to controller 206 . The controller proceeds to step 313 if such data is received from the accelerometer 205 , otherwise proceeds to step 320 .

In step 313, the measured GSR is ignored. In this example, upon identifying user movement, controller 206 concludes that the measured GSR is outside the reference range due to such movement. Accordingly, the controller 206 disregards the measured GSR for that period of time because it is unlikely that the measured GSR is indicative of the user's actual stress level. In this way any errors caused by user movements are avoided. Controller 206 then proceeds to step 309 and checks the puff data as described above.

FIG. 4 shows a graph 400 of a user's varying stress levels over a typical week. The days of the week may be plotted on the X-axis and stress levels plotted on the Y-axis to depict the user's stress pattern. In this example, the user's stress pattern resembles a sinusoidal waveform of varying amplitude. A flat line overlying the stress pattern represents a default stress criterion that is not optimized for a particular user over a given period of time. However, for any given day, a user's stress level may vary throughout the day, starting with low stress in the morning, peaking during the day, and dropping again at night. Throughout the week, stress levels may vary from day to day. Typically, stress can be higher on weekdays and lower on weekends. In the illustrated example, Wednesday is the most stressful day, eg, due to a high workload, and Saturday is the least stressful day, eg, due to leisure time at home.

It should be understood that graph 400 represents only one possible example of a user's stress patterns given a typical week. Different users with different lifestyles may have completely different patterns. For example, a user who works weekends or night shifts may have higher stress levels during weekends and nights. Stress patterns are also different when the user is away from work, eg during holidays or social events. The controller 206 therefore continuously monitors the user's stress patterns over different time periods and continues to learn to update the reference range. It should also be appreciated that the graph 400 shows changes in stress over time and that the reference range has been simplified as a curve for simplicity without showing upper and lower limits.

FIG. 5 shows a graph 500 of a user's GSR data at different time periods. In graph 500, the X-axis has the time period over which stress levels are measured and the Y-axis has GSR or skin conductance values in microsiemens (μS). Galvanometer 204 measures the user's galvanic skin response, which controller 206 records at each time slot. As explained above, the controller 206 also identifies the user's reference range with upper and lower reference limits. The controller 206 also identifies upper safety limits that are either user-specific or pre-specified by default. As shown, in the first period, the user's GSR is specified to be 3 μS, which is within the range between the reference upper limit of 4 and the reference lower limit of 2. However, in the second period, the measured GSR is 12 μS, which is higher than the upper reference limit of 10. As explained above, the controller 206 adjusts the amount of substance in the aerosol when it determines that the measured GSR is outside the reference range. The controller 206 thus ensures that the user's stress level remains at an optimum level over time of the day or according to the user's preferences. In this example, the measured GSR is always below the upper safe limit.

Using the invention described above, it is possible to monitor a user's stress level without using any additional equipment or requiring the user to perform any additional steps. Moreover, by controlling the delivery of the aerosol based on the identified stress level, it is possible to keep the user's stress level at a baseline or optimal level most of the time. This allows users to enjoy vaping without having to consciously monitor their aerosol intake.

In the invention described above, stress readings may be presented to the user through a small display on the inhaler. It may also be possible to warn the user of a high or low stress level by flashing different colored LEDs or by emitting a warning sound. Additionally or alternatively, a mobile phone that may run an application (such as an iOS/Android app) that displays the current stress level, exercise data, puff data, aerosol intake, etc. in a user-friendly format for the user of the inhaler. Or it is possible to connect the inhaler to the user's personal device, such as a smart phone. Such a device may also be configured, when connected to an inhaler, to receive various measurements from the inhaler and identify criteria as described above.

The foregoing description of illustrative embodiments has been presented for purposes of illustration and description. It is not intended to be exhaustive or limiting with respect to the precise forms disclosed, and modifications and variations are possible in light of the above teachings or may be acquired from practice of the disclosed embodiments. .

Claims (15)

An aerosol-generating vaping device,
a housing having an air flow path defined between an air inlet and an air outlet of said housing, said air outlet allowing generated aerosol to exit;
a galvanometer disposed on the body of the vaping device, the galvanometer configured to measure galvanic skin response to identify a stress level of a user of the vaping device;
a controller configured to control the release of the aerosol based on the determined stress level, the controller using the measurements made by the galvanometer over different time periods to generate a reference galvanic skin for the user; a controller further configured to specify a response. The galvanometer is integrated with the activation switch of the vaping device such that when the user interacts with the activation switch to activate the vaping device, the user's skin contacts the galvanometer. 2. The aerosol-generating vaping device of claim 1, wherein the aerosol-generating vaping device is 3. The galvanometer is disposed on a side of the vaping device such that when the user holds the vaping device during use, the user's skin contacts the galvanometer. 3. The aerosol-generating vaping device according to 2. An aerosol-generating vaping device according to any preceding claim, wherein the vaping device further comprises an accelerometer for detecting the movement of the user when using the vaping device. 5. The aerosol-generating vaping device of Claim 4, wherein the controller is configured to ignore the galvanic skin response measured by the galvanometer based on the movement detected by the accelerometer. 6. The aerosol-generating vaping device of any one of claims 1-5, wherein the reference galvanic skin response comprises a range having an upper reference limit and a lower reference limit. 7. The aerosol-generating vaping device of claim 6, wherein the controller is configured to increase or decrease the amount of substance in the aerosol if the measured galvanic skin response is outside the reference galvanic skin response. An aerosol-generating vaping device according to any preceding claim, wherein the controller is configured to specify the number of puffs inhaled by the user per unit time or the average duration of puffs. A method of operating an aerosol-generating vaping device comprising:
activating the vaping device to emit an aerosol from the vaping device;
measuring galvanic skin response to determine a user's stress level using a galvanometer disposed on the body of the vaping device;
controlling the release of the aerosol based on the identified stress level, wherein a baseline galvanic skin response is identified for the user using the measurements made by the galvanometer over different time periods; A method comprising: 10. The method of claim 9, further comprising detecting movement of the user when using the vaping device. 11. The method of claim 10, further comprising ignoring the galvanic skin response measured by the galvanometer based on the detected motion. The method of any one of claims 9 to 11, wherein the reference galvanic skin response comprises a range having an upper reference limit and a lower reference limit. Further comprising increasing or decreasing the amount of the substance in the aerosol if the measured galvanic skin response is outside the reference galvanic skin response. Method. Further comprising increasing or decreasing the amount of the substance in the aerosol based on the number of puffs inhaled by the user per unit time or the average duration of puffs. The method described in . When executed by a processor, causing said processor to:
receiving measurements of the user's galvanic skin response;
determining a baseline galvanic skin response for the user using the measurements received over different time periods;
A computer-readable storage medium comprising instructions for controlling aerosol emission based on said baseline galvanic skin response.

Images